OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $3.91M fell 2.0% year over year, behind the +87.7% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 14.8% from the prior quarter. Over 3 fiscal years it compounded at +55.5% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +38.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.91M+14.8% QoQ
- Last fiscal yearDec 2025
- $14.69M+38.7% YoY
- LTMMar 2026
- $14.61M+87.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.0% | -100.0% | -98.0 pp |
| 1 year | +38.7% | -100.0% | -138.7 pp |
| 3-year CAGR | +55.5% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 14.69M USD
- Year-over-year change
- +38.7%
- 4-year CAGR
- +6.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.69M | +38.7% |
| FY2024 | 2024-12-31 | 10.59M | +119.8% |
| FY2023 | 2023-12-31 | 4.82M | +23.4% |
| FY2022 | 2022-12-31 | 3.9M | -66.5% |
| FY2021 | 2021-12-31 | 11.65M | — |
Selling, General & Admin vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's LTM Mar 2026 selling, general & admin of $14.61M is the 3rd highest of the 4 companies compared; the peer median is $27.78M.
- Its year-over-year change of +87.7% is the 2nd highest of 4, against a peer median of +2.3%.
- Over three fiscal years its annual growth of +55.5% compares with a peer median of +0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.07B | +22461.6% | +0.7% | — | |
| LTM Mar 2026 | $27.78M | +2.3% | -0.3% | 51.9% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $14.61M | +87.7% | +55.5% | — |
| LTM Jun 2026 | $7.41M | -56.6% | +8.2% | 21.1% | |
| Peer median (excluding OKUR) | $27.78M | +2.3% | +0.7% | 36.5% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 50K | 0 | 0 | 0 | 830K |
| Gross Profit | (50K) | 0 | 0 | 0 | (830K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 28.12M | 25.86M | 32.12M | 43.8M | 48.26M |
| Selling, General & Admin | 11.65M | 3.9M | 4.82M | 10.59M | 14.69M |
| Operating Expenses | 39.77M | 29.77M | 36.93M | 54.39M | 62.12M |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| EBITDA | (39.72M) | (29.13M) | (34.75M) | (51.71M) | (58.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (39.82M) | (29.77M) | (36.93M) | (54.39M) | (62.95M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 254K | 1.62M | 2.01M | 3.44M |
| Interest Expense | 0 | 0 | 0 | 300K | 0 |
| Other Income / Expenses | 48K | 254K | 1.62M | 1.71M | 3.43M |
| Income Before Tax | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (21.92) | (2.21) | (2.65) | (3.95) | (4.40) |
| EPS (Diluted) | (21.92) | (2.21) | (2.65) | (3.95) | (4.40) |
| Weighted Avg Shares | 1.81M | 13.34M | 13.34M | 13.34M | 13.52M |
| Weighted Avg Shares (Diluted) | 1.81M | 13.34M | 13.34M | 13.34M | 13.52M |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.